The iShares U.S. Pharmaceuticals ETF heads into the week with a tightening borrow market and rising options caution, even as short sellers modestly trim their positions.
The lending picture here is the standout story. Availability has fallen sharply — down 64% over the past week to just 21.4%, meaning roughly one share remains available for every four already borrowed. That is tight, though still above the 52-week floor of 9%, which the ETF touched in late April. Cost to borrow has also eased back from that late-April spike — on April 23 it briefly hit 94.8%, a clear outlier — and has since settled around 7.1%. The directional move in borrow demand is worth noting: availability fell hard this week even as short interest itself declined 4.3% over the same period to 6.1% of float. That combination — fewer shorts, but tighter borrow — suggests the remaining short base is holding its ground rather than capitulating, and competition for available shares is intensifying.
Short interest tells a more nuanced story than the availability alone. At 6.1% of float, the level remains meaningful for an ETF product. However, it has pulled back from a recent high of around 9% of float set in early April, when availability was testing its lowest levels of the year. The ORTEX short score of 66.5 is elevated — consistent with a fund where short positioning is a considered, active trade rather than incidental. That score has been broadly stable over the past two weeks, moving narrowly between 65.7 and 67.5, suggesting the bearish conviction in the lending market has not shifted dramatically in either direction.
Options positioning adds a layer of caution. The put/call ratio has climbed to 0.23, running well above its 20-day average of 0.096 — a z-score of 1.4, the most defensive reading the ETF has shown in roughly a month. The absolute PCR remains moderate; it spiked as high as 5.57 in the past year. But the direction of travel is clear: relative to recent norms, options traders are hedging more than they were. That aligns with the broader picture for health care ETFs, which have seen net outflows of approximately $2 billion over the past month according to sector fund flow data — second only to financials in net redemptions across all sectors.
Institutional ownership context rounds out the picture. Fisher Asset Management holds the largest reported stake at 40.1% of shares as of end-March, with a modest trim of around 58,000 shares. Aptus Capital Advisors and McElhenny Sheffield Capital Management both initiated or dramatically expanded positions in Q1, each adding over 200,000 shares. JPMorgan added 163,000 shares in the same period. This suggests a degree of active institutional conviction on both sides — some trimming at the top, meaningful fresh buying from wealth managers.
The ETF closed at $88.55 on May 19, up 1.3% on the day and 0.6% on the week, though still marginally lower over the past month. With the borrow pool continuing to tighten and health care sector fund flows negative, the watch point is whether availability drops back toward its April lows — the last time it did, borrowing costs briefly went parabolic.
See the live data behind this article on ORTEX.
Open IHE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
